{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:32:10Z","timestamp":1793831530631,"version":"4.6.1"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"\n Importance<\/jats:title>\n Programmed cell death 1 ligand 1\/programmed cell death protein 1 inhibitors, with or without chemotherapy, are standard first-line treatment for patients with advanced non\u2013small cell lung cancer (NSCLC); however, survival benefit is limited, and many patients experience disease progression.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n SKYSCRAPER-06 was a phase 3 randomized clinical trial that recruited patients with previously untreated, locally advanced unresectable or metastatic NSCLC at 129 sites in 21 countries between December 15, 2020, and September 14, 2023 (data cutoff, April 19, 2024).<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n \n Patients were randomized 1:1 to receive either tiragolumab, 600 mg, plus atezolizumab, 1200 mg, plus chemotherapy (pemetrexed, 500 mg\/m\n 2<\/jats:sup>\n , and carboplatin [area under the curve 5], or cisplatin, 75 mg\/m\n 2<\/jats:sup>\n ) or placebo plus pembrolizumab, 200 mg, plus chemotherapy via intravenous infusion on day 1 of each 21-day cycle until disease progression, loss of clinical benefit, unacceptable toxic effect, or withdrawal of consent.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary end points were investigator-assessed progression-free survival and overall survival. The safety and tolerability of the study drugs were also evaluated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 542 patients in the full analysis set (mean [SD] age, 63.6 [9.3] years; 353 [65.1%] male), 269 were randomized to tiragolumab plus atezolizumab plus chemotherapy and 273 to placebo plus pembrolizumab plus chemotherapy. Overall, baseline demographics were similar between treatment groups. At data cutoff (median follow-up, 11.8 months), median investigator-assessed progression-free survival was 8.3 months (95% CI, 7.1-9.6 months) with tiragolumab plus atezolizumab plus chemotherapy vs 9.9 months (95% CI, 8.7-11.9 months) with placebo plus pembrolizumab plus chemotherapy (hazard ratio, 1.27; 95% CI, 1.02-1.57;\n P<\/jats:italic>\n \u2009=\u2009.99); median overall survival was 18.9 months (95% CI, 15.2-23.8 months) vs 23.1 months (95% CI, 20.7-33.0 months) in each treatment group, respectively (hazard ratio, 1.33; 95% CI, 1.02-1.73;\n P<\/jats:italic>\n \u2009=\u2009.98). Grade 3 to 4 adverse events occurred in 164 of 267 patients (61.4%) in the tiragolumab plus atezolizumab plus chemotherapy group and 165 of 272 patients (60.7%) in the placebo plus pembrolizumab plus chemotherapy group, with grade 5 AEs occurring in 27 of 267 patients (10.1%) and 16 of 272 patients (5.9%) in each group, respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In the phase 3 SKYSCRAPER-06 randomized clinical trial, the primary end points were not met and the study has been terminated.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04619797<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.0818","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:31:21Z","timestamp":1777563081000},"page":"619","source":"Crossref","is-referenced-by-count":10,"title":["Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"Mark A.","family":"Socinski","sequence":"first","affiliation":[{"name":"Thoracic Oncology Program, AdventHealth Cancer Institute, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Stahel","sequence":"additional","affiliation":[{"name":"ETOP IBCSG Partners Foundation, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cappuzzo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Lovly","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Ozyilkan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Baskent University Hospital, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Affiliated Hospital of Chengde Medical College, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles"},{"name":"TRIO-US Network, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, \u0130stinye University Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio Augusto","family":"Ferreira da Silva","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Barretos Cancer Hospital, Barretos, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alatorre-Alexander","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de Oncolog\u00eda Tor\u00e1cica, Health Pharma Professional Research, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Meng","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Amin","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Matheny","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Troutman","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wen","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata S.","family":"Patil","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zou","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delvys","family":"Rodriguez-Abreu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Insular de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"13","key":"coi260014r1","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","article-title":"Global burden and trends of lung cancer incidence and mortality.","volume":"136","author":"Li","year":"2023","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"coi260014r2","first-page":"12","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"coi260014r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-24223-1","article-title":"Lung Cancer Statistics.","volume":"893","author":"Torre","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"24","key":"coi260014r5","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"coi260014r6","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer.","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"coi260014r7","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"coi260014r8","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"coi260014r9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi260014r10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial.","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"coi260014r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104683","article-title":"Resistance to PD-1\/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer.","volume":"209","author":"Li","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"coi260014r12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade.","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J"},{"issue":"4","key":"coi260014r13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004711","article-title":"TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.","volume":"10","author":"Chiang","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"coi260014r14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle.","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol"},{"issue":"6","key":"coi260014r15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"issue":"14","key":"coi260014r16","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC.","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"10308","key":"coi260014r17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"10400","key":"coi260014r18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(23)00774-2","article-title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.","volume":"402","author":"Lee","year":"2023","journal-title":"Lancet"},{"issue":"8004","key":"coi260014r21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"issue":"11","key":"coi260014r22","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jamaoncol.2023.3867","article-title":"Anti-TIGIT antibody tiragolumab alone or with atezolizumab in patients with advanced solid tumors: a phase 1a\/1b nonrandomized controlled trial.","volume":"9","author":"Kim","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"coi260014r23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi260014r24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation.","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"coi260014r25","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.molimm.2007.08.013","article-title":"Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.","volume":"45","author":"Zhang","year":"2008","journal-title":"Mol Immunol"},{"issue":"7","key":"coi260014r26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12032-019-1285-x","article-title":"Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer.","volume":"36","author":"Yoshida","year":"2019","journal-title":"Med Oncol"},{"issue":"4","key":"coi260014r32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"coi260014r33","doi-asserted-by":"publisher","first-page":"CT051","DOI":"10.1158\/1538-7445.AM2025-CT051","article-title":"SKYSCRAPER-01: a phase III, randomized trial of tiragolumab + atezolizumab versus placebo + in patients with previously untreated PD-L1-high, locally advanced unresectable\/metastatic NSCLC.","volume":"85","author":"Peters","year":"2025","journal-title":"Cancer Res"},{"key":"coi260014r34","doi-asserted-by":"publisher","first-page":"S1242","DOI":"10.1016\/j.annonc.2024.08.2294","article-title":"LBA52 interim analysis of GALAXIES Lung-201: phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced\/metastatic (LA\/M) PD-L1 high (TPS =50%) non-small cell lung cancer (NSCLC).","volume":"35","author":"Spigel","year":"2024","journal-title":"Ann Oncol"},{"issue":"21","key":"coi260014r35","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score =50%: randomized, double-blind phase III KEYNOTE-598 study.","volume":"39","author":"Boyer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi260014r36","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","article-title":"Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: a randomized, open-label, phase 3 trial.","volume":"18","author":"Cho","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"6","key":"coi260014r37","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jtho.2023.12.023","article-title":"Pembrolizumab with or without lenvatinib for first-line metastatic NSCLC with programmed cell death-ligand 1 tumor proportion score of at least 1% (LEAP-007): a randomized, double-blind, phase 3 trial.","volume":"19","author":"Yang","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"3","key":"coi260014r38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cllc.2023.12.010","article-title":"STAR-121: a phase III randomized study of domvanalimab and zimberelimab in combination with chemotherapy versus pembrolizumab with chemotherapy in untreated metastatic non-small cell lung cancer with no actionable gene alterations.","volume":"25","author":"Rodriguez-Abreu","year":"2024","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"coi260014r39","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"issue":"1","key":"coi260014r40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13046-024-02960-w","article-title":"T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution.","volume":"43","author":"Yang","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"coi260014r41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"coi260014r42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy.","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"coi260014r43","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s43018-024-00870-6","article-title":"TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation.","volume":"5","author":"Nutsch","year":"2024","journal-title":"Nat Cancer"},{"key":"coi260014r4","unstructured":"Howlader? N, Noone? AM, Krapcho? M, . SEER Cancer Statistics Review (CSR), 1975\u20132017: lung and bronchus. National Cancer Institute. April 15, 2020. Accessed June 9, 2025. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2017\/index.html"},{"key":"coi260014r19","unstructured":"Tecentriq. Prescribing information. Genentech; 2025. Accessed July 02, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761034s057lbl.pdf"},{"key":"coi260014r20","unstructured":"Tecentriq: summary of product characteristics. European Medicines Agency. Accessed July 02, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecentriq-epar-product-information_en.pdf"},{"key":"coi260014r27","unstructured":"iTeos reports topline interim results from GALAXIES Lung-201 study of belrestotug + dostarlimab in first-line, PD-L1 high non-small cell lung cancer patients. News release. BioSpace. May 14, 2025. Accessed March 29, 2026. https:\/\/www.biospace.com\/press-releases\/iteos-reports-topline-interim-results-from-galaxies-lung-201-study-of-belrestotug-dostarlimab-in-first-line-pd-l1-high-non-small-cell-lung-cancer-patients"},{"key":"coi260014r28","unstructured":"Merck provides update on KeyVibe and KEYFORM clinical development programs evaluating investigational vibostolimab and favezelimab fixed-dose combinations with pembrolizumab. News release. Merck. December 16, 2024. Accessed July 31, 2025. https:\/\/www.merck.com\/news\/merck-provides-update-on-keyvibe-and-keyform-clinical-development-programs-evaluating-investigational-vibostolimab-and-favezelimab-fixed-dose-combinations-with-pembrolizumab\/"},{"key":"coi260014r29","unstructured":"BeiGene provides update on the ociperlimab (BGB-A1217) clinical development program. News release. BeOne Medicines. April 3, 2025. Accessed July 31, 2025. https:\/\/ir.beonemedicines.com\/news\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/4f7a71c1-cb84-4fa6-b562-65c239f04bc6"},{"key":"coi260014r30","unstructured":"Genentech provides update on phase II\/III Skyscraper-06 study in metastatic non-squamous non-small cell lung cancer. News release. Genentech. July 3, 2024. Accessed July 02, 2025. https:\/\/www.gene.com\/media\/press-releases\/15029\/2024-07-03\/genentech-provides-update-on-phase-iiiii"},{"key":"coi260014r31","unstructured":"Keytruda. Prescribing information. Merck; 2024. Accessed July 02, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125514s172lbl.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2848246\/jamaoncology_socinski_2026_oi_260014_1781656669.17912.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:00:54Z","timestamp":1781794854000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2848246"}},"subtitle":["The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.0818","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}